Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

被引:23
|
作者
Facchinetti, Fabrizio [1 ]
Civelli, Maurizio [1 ]
Singh, Dave [2 ]
Papi, Alberto [3 ]
Emirova, Aida [4 ]
Govoni, Mirco [4 ]
机构
[1] Corp Preclin R&D, Parma, Italy
[2] Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England
[3] Univ Ferrara, Dept Translat Med, Resp Med, Ferrara, Italy
[4] Global Clin Dev, Parma, Italy
关键词
phosphodiesterase 4 inhibitors (PDE4i); asthma; COPD-chronic obstructive pulmonary disease; inhaled administration; inflammation; SURFACTANT PROTEIN-D; METERED-DOSE INHALER; PHOSPHODIESTERASE-4; INHIBITOR; EOSINOPHILIC INFLAMMATION; PRECLINICAL PHARMACOLOGY; TRIPLE THERAPY; CYCLIC-AMP; ROFLUMILAST; COPD; CHF6001;
D O I
10.3389/fphar.2021.740803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] PERIODIC TREATMENT REGIMENS WITH INHALED STEROIDS IN ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY-DISEASE - IS IT POSSIBLE
    VANSCHAYCK, CP
    VANDENBROEK, PJJA
    DENOTTER, JJ
    VANHERWAARDEN, CLA
    MOLEMA, J
    VANWEEL, C
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (02): : 161 - 164
  • [22] Responsiveness To Inhaled Corticosteroid Treatment In Patients With Asthma And Chronic Obstructive Pulmonary Disease Overlap Syndrome
    Lim, H.
    Choi, S.
    Lee, J.
    Park, Y.
    Lee, S. -M.
    Yim, J. -J.
    Yoo, C. -G.
    Kim, Y.
    Han, S.
    Lee, C. -H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [23] Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma
    Lu, Susan
    Liu, Nancy
    Dass, S. Balachandra
    Reiss, Theodore F.
    Knorr, Barbara A.
    RESPIRATORY MEDICINE, 2009, 103 (03) : 342 - 347
  • [24] Preclinical Pharmacokinetics of PDE-310, a Novel PDE4 Inhibitor
    Song, Jin Sook
    Rho, Hyeong Jin
    Park, Jong Shik
    Kim, Min Sun
    Lee, Byung Hoi
    Seo, Jeong-won
    Jeon, Dong Ju
    Cheon, Hyae Gyeong
    Ahn, Sung Hoon
    Kwon, Kwang-il
    Bae, Myung Ae
    DRUG METABOLISM AND PHARMACOKINETICS, 2011, 26 (02) : 192 - 200
  • [25] Asthma and chronic obstructive pulmonary disease overlap: asthmatic chronic obstructive pulmonary disease or chronic obstructive asthma?
    Slats, Annelies
    Taube, Christian
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (01) : 57 - 71
  • [26] Pharmacology of a Novel, Orally Active PDE4 Inhibitor
    Dastidar, Sunanda G.
    Ray, Abhijit
    Shirumalla, Rajkumar
    Rajagopal, Deepa
    Chaudhary, Shiwani
    Nanda, Kamna
    Sharma, Pawan
    Seth, Mahesh Kumar
    Balachandran, Sarala
    Gupta, Nidhi
    Palle, Venkata
    PHARMACOLOGY, 2009, 83 (05) : 275 - 286
  • [27] Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
    Giembycz, MA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (07) : 1361 - 1379
  • [28] Tetomilast -: Treatment of inflammatory bowel disease treatment of COPD antioxidant PDE4 inhibitor
    McIntyre, JA
    Castañer, J
    Castañer, RM
    DRUGS OF THE FUTURE, 2004, 29 (10) : 1003 - 1006
  • [29] Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
    Singh, Dave
    Lea, Simon
    Mathioudakis, Alexander G.
    DRUGS, 2021, 81 (16) : 1821 - 1830
  • [30] Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
    Dave Singh
    Simon Lea
    Alexander G. Mathioudakis
    Drugs, 2021, 81 : 1821 - 1830